Novo Nordisk Just Gave Wegovy to Six-Year-Olds. It Worked.
Novo Nordisk's STEP Young trial showed 40% of children as young as six were no longer classified as obese after 68 weeks on semaglutide, while zero on placebo crossed that line. The results are forcing a reckoning over GLP-1 drugs in elementary schoolers, and the insurance fights haven't even started yet.
Imagine telling a parent that a weekly injection could move their child out of obesity in just over a year. Now imagine that child is in first grade.
That's the headline from Novo Nordisk's STEP Young trial, and it's raising eyebrows across pediatrics, Wall Street, and insurance boardrooms all at once.
The Number That Changes Everything
In the phase 3 STEP Young trial, 40.4% of children aged 6 to 11 who received semaglutide (the drug behind Wegovy) were no longer classified as obese after 68 weeks of treatment. The placebo group? Zero percent crossed that threshold. Not a single kid.
Let that sink in. Four out of ten children on semaglutide went from clinically obese to either overweight or normal weight, while every child on placebo stayed right where they started. And many of these kids had severe obesity at baseline, which makes the reclassification even more striking.
The trial enrolled 165 children, all paired with lifestyle changes like healthier diets and more physical activity. Semaglutide was given as a once-weekly injection, starting at 0.25 mg and gradually escalating over 16 weeks to a maintenance dose of 2.4 mg. Both the primary endpoint (percent change in BMI from baseline) and the confirmatory secondary endpoint (improvement in BMI classification) were met.
This isn't a marginal win. It's a blowout.
Why Pediatricians Are Paying Attention
To understand why this matters so much, you need to know what doctors currently have in their toolkit for a seven-year-old with obesity. The answer: not much.
The standard of care for children ages 6 to 12 is essentially family-based behavioral therapy. Think structured programs focused on eating habits, exercise, and behavior change. These programs work to a degree, but multiple reviews have found them insufficient for kids with more severe obesity or families who can't consistently access them. It's a bit like telling someone with a broken leg to try stretching.
Medications? Almost entirely off the table. Anti-obesity drugs have traditionally been reserved for who don't respond to lifestyle changes alone. Bariatric surgery exists for severe cases, but it's a last resort for teens, not elementary schoolers. For the 6-to-11 crowd, the pharmacotherapy cupboard has been essentially bare.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
adolescents 12 and older
That's the gap STEP Young just drove a truck through.
How Semaglutide Stacks Up
Semaglutide isn't the first GLP-1 receptor agonist (a class of drugs that mimics a gut hormone to reduce appetite and regulate blood sugar) tested in kids. But it's clearly the strongest performer.
Liraglutide, the older sibling in Novo Nordisk's portfolio, has been studied in pediatric populations too. Its results were much more modest: roughly 4 to 6% BMI reduction over about 56 weeks. Compare that to semaglutide's performance in the STEP TEENS trial (ages 12 and up), which delivered around 16% BMI reduction over 68 weeks. That's roughly three to four times the effect.
What about tirzepatide, Eli Lilly's dual-action competitor? Despite being a blockbuster in adults, it doesn't yet have published pediatric obesity trial data. So for now, semaglutide is running this race alone in children under 12.
The STEP Young results appear to extend semaglutide's dominance from teens down to kids as young as six, which is a much bigger deal than it might sound. Proving something works in a 15-year-old is one thing. Proving it works in a child whose body is still growing, whose hormones haven't kicked in yet, and whose relationship with food is still being shaped by parents and school cafeterias: that's a different challenge entirely.
The Safety Question Everyone's Asking
Whenever you put a powerful drug in young children, the first question is always safety. Especially when the drug suppresses appetite in kids who are still developing.
Novo Nordisk reported that the overall safety profile was consistent with what's been seen in previous semaglutide and liraglutide trials. The most common side effects were gastrointestinal issues like nausea and diarrhea, which tracks with GLP-1 drugs across every age group. More importantly, the company said there were no safety signals for growth or pubertal development, which is the concern that keeps pediatricians up at night.
That said, a few caveats are worth noting. The trial had only 165 participants, and 68 weeks, while meaningful, doesn't tell us what happens over five or ten years of a child's development. We don't yet know how durable the weight loss is after the injections stop. And these findings come from a company press release, not a peer-reviewed publication. The full dataset still needs to be independently scrutinized.
Promising? Absolutely. Case closed? Not yet.
The Regulatory Maze Ahead
Right now, Wegovy is FDA-approved for patients 12 and older with obesity (defined as a BMI at or above the 95th percentile for age and sex). That green light came in December 2022. For children under 12, the prescribing label is clear: safety and effectiveness have not been established.
As of 2026, FDA documents show that Novo Nordisk's pediatric study requirement for ages 6 to under 18 (specifically for a newer 7.2 mg dose) is deferred, meaning the studies aren't complete. So any use of semaglutide in a child under 12 right now would be off-label.
The STEP Young data could change that trajectory significantly. A positive readout is typically the first step toward filing a supplemental approval, which would expand the label down to younger children. The trial's completion is estimated for December 2026, so a regulatory submission could follow in 2027 at the earliest. But FDA timelines are famously unpredictable, and pediatric reviews tend to get extra scrutiny.
The Payer Problem
Even if the FDA eventually says yes, the bigger battle might be with insurance companies. And if you think getting coverage for Wegovy is hard for adults (spoiler: it is), imagine the conversation about covering it for six-year-olds.
Payers are likely to demand a laundry list before opening the checkbook: published trial data, age-specific safety outcomes, evidence that weight loss persists after stopping treatment, proof that medication is paired with structured lifestyle therapy, and detailed documentation of how severe the child's obesity is. Prior authorization requirements will almost certainly be strict.
The most realistic near-term scenario is selective coverage for severe pediatric obesity in specialist settings, not a broad green light for any overweight elementary schooler. Broad insurer adoption typically follows a predictable sequence: regulatory approval, guideline incorporation, and accumulation of real-world safety data. Each of those steps takes time.
The Bigger Picture
The debate over giving GLP-1 drugs to young children isn't just medical. It's cultural.
Childhood obesity affects roughly one in five kids in the U.S., and rates have been climbing for decades. The consequences ripple forward into adulthood: higher risks of diabetes, heart disease, joint problems, and mental health challenges. Behavioral interventions help, but they haven't reversed the trend. For many families, the options have felt limited and the outcomes discouraging.
STEP Young changes the math. It introduces a tool that, in a controlled trial, moved four out of ten children below the obesity threshold. That's powerful. It's also complicated. Questions about long-term effects on growing bodies, the ethics of medicating young children for a condition with deep social and environmental roots, and the sheer cost of treatment aren't going away.
But the conversation has shifted. Before STEP Young, the question was: Should we even consider medication for children this young? Now the question is: How do we responsibly make it available?
That's a very different question. And answering it will require pediatricians, regulators, payers, and parents to navigate some genuinely uncharted territory.
What Happens Next
The full STEP Young dataset should arrive before the end of 2026. Expect it to be one of the most talked-about presentations at whichever medical conference gets to debut it. Peer review will follow, and that's when the real scrutiny begins.
In the meantime, Novo Nordisk has dropped a data bomb that will force faster decisions from the AAP (American Academy of Pediatrics), the FDA, and every major insurer in the country. Pediatric obesity treatment guidelines, which already recommend pharmacotherapy for children 12 and older when lifestyle interventions aren't enough, may need to be rewritten for younger kids.
The era of treating childhood obesity with diet advice and good intentions isn't over. But it just got a very powerful co-pilot.
Deals & M&A4 min read
Lilly's $2.9B Bet on a Disease Most People Have Never Heard Of
Eli Lilly just dropped up to $2.875 billion on a startup whose lead drug hasn't even finished Phase 1 testing. The target: a precision platform that hunts down disease-causing antibodies one by one. It's either the smartest bet in autoimmune disease or the most expensive appetizer in pharma history.
